Inflammatory cytokines, T lymphocyte subsets, and ritonavir involved in liver injury of COVID-19 patients
Shengtao Liao, Ke Zhan, L. H. Gan, Yang Bai, Jinfang Li, Guodan Yuan, Ying Cai, An Zhang, Song He, Zhechuan Mei
Abstract
) is a type of novel coronavirus and no specific treatment is currently available. Apart from damages to the lung, COVID-19 is also able to trigger liver injury. Numerous observational studies have revealed that elevation of liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), was detected in some COVID-19 patients, especially in severe cases. Therefore, identification of novel risk factors in liver injury of COVID-19 patients is essential for the prevention and treatment of liver damage. In this study, 192 patients with COVID-19 hospitalized in Chongqing Public Health Center were recruited to identify the risk factors in COVID-19 patients with liver injury.